Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study
Journal of Internal Medicine · 2025
DOI: 10.1111/joim.20030 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Ilaria Mastrorosa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To estimate the risk of COVID‐19‐related hospitalization and death (CovH/D), among high‐risk individuals early treated for COVID‐19 and to identify associated factors. Methods and results A multicenter cohort of 12,475 high‐risk outpatients (female 50.2%, median age 70 years [IQR 57–80], fully vaccinated 79.1%, immunocompromised 23.2%) treated with monoclonal antibodies or antivirals for mild‐to‐moderate COVID‐19 (March 2021–May 2023) in the Lazio region, Italy. The unadjusted risk of CovH/D by Day 30 was 3.08% (95% CI 2.7%–3.4%). By means of logistic regression models, which included a specific set of potential confounders for each exposure of interest, we observed a higher risk for the elderly, unvaccinated and immunocompromised participants. Using the “Delta period” as a reference, a decreased risk was observed for Omicron waves.
Conclusions
Despite the administration of COVID‐19 early treatment and the decreasing risk of CovH/D across the calendar periods, the elderly, the unvaccinated and the immunocompromised people remain at high risk of clinical progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
- Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy.
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
- Infectious Diseases Unit, Tor Vergata University Hospital, Rome, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Ilaria Mastrorosa
Zitieren
APA
Mastrorosa, I., Lepri, A. C., Borgo, C. D., Rosati, S., Rueca, M., Sarmati, L., Mastroianni, C., Fantoni, M., Maggi, F., Nicastri, E., Girardi, E., Lichtner, M., Antinori, A., Mazzotta, V., & Early Treatment for COVID‐19 Lazio Study Group (2025). Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study. Journal of Internal Medicine. https://doi.org/10.1111/joim.20030
Vancouver
Mastrorosa I, Lepri AC, Borgo CD, Rosati S, Rueca M, Sarmati L, et al. Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study. Journal of Internal Medicine. 2025. doi:10.1111/joim.20030
BibTeX
@article{Mastrorosa2025,
author = {Mastrorosa, Ilaria and Lepri, Alessandro Cozzi and Borgo, Cosmo Del and Rosati, Silvia and Rueca, Martina and Sarmati, Loredana and Mastroianni, Claudio and Fantoni, Massimo and Maggi, Fabrizio and Nicastri, Emanuele and Girardi, Enrico and Lichtner, Miriam and Antinori, Andrea and Mazzotta, Valentina and Early Treatment for COVID‐19 Lazio Study Group, Early Treatment for COVID‐19 Lazio Study Group},
title = {Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study},
journal = {Journal of Internal Medicine},
year = {2025},
doi = {10.1111/joim.20030}
}
EUVIMED